PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report published on Wednesday morning,Benzinga reports. They currently have a $21.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley cut their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, November 25th. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.67.

PDS Biotechnology Trading Down 7.9 %

Shares of NASDAQ:PDSB opened at $1.81 on Wednesday. The business has a 50-day moving average price of $2.64 and a 200-day moving average price of $3.04. The stock has a market cap of $67.52 million, a price-to-earnings ratio of -1.56 and a beta of 1.85. PDS Biotechnology has a 52-week low of $1.53 and a 52-week high of $6.68. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Trading of PDS Biotechnology

Several institutional investors have recently bought and sold shares of the business. Tempus Wealth Planning LLC purchased a new position in shares of PDS Biotechnology during the 2nd quarter valued at approximately $55,000. Ground Swell Capital LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at about $67,000. Blair William & Co. IL raised its position in shares of PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after purchasing an additional 81,743 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in PDS Biotechnology in the 2nd quarter valued at about $146,000. Finally, Squarepoint Ops LLC acquired a new stake in PDS Biotechnology in the 2nd quarter worth about $120,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.